[Correlation analysis of FPGS rs10760502G>a polymorphism with prognosis and MTX-related toxicity in pediatric B-cell acute lymphoblastic leukemia].

Abstract

This study was aimed to explore the relation between folylpolyglutamate synthetase (FPGS) rs10760502 polymorphism and prognosis and methotrexate (MTX)-related toxicities in pediatric B-cell acute lymphoblastic leukemia (B-ALL). Sequenom MassARRAY was used to genotype rs10760502. The χ(2) test, Kaplan-Meier method and Cox regression models were used to analyze the data. The results indicated that A allele carriers (GA+AA) had poor relapse free survival (RFS, log-rank: P = 0.004) and event free survival (EFS, log-rank: P = 0.022) compared with the GG genotype carriers. Multivariate Cox-regression analysis results showed that A allele is an independent prognosis factor for poor RFS [hazard ratio (HR), 20.173; 95% CI, 2.535-160.545; P = 0.005] and EFS (HR, 8.133; 95% CI, 1.718-38.512; P = 0.008). No relationship was found between any MTX toxicity and rs10760502 polymorphism. It is concluded that FPGS rs10760502G>A polymorphism may affect the treatment outcome of B-ALL patients.

• Authors: Shu-Guang Liu, Chao Gao, Zhi-Gang Li, Wei-Jing Li, Lei Cui, Xiao-Xi Zhao, Hu-Yong Zheng, Min-Yuan Wu, Rui-Dong Zhang
• Journal: Zhongguo shi yan xue ye xue za zhi (Zhongguo Shi Yan Xue Ye Xue Za Zhi) Vol. 22 Issue 2 Pg. 291-7 (Apr 2014) ISSN: 1009-2137 [Print] China
• PMID: 24762994 (Publication Type: English Abstract, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Peptide Synthases
• folylpolyglutamate synthetase
• Methotrexate

Topics

• Adolescent
• Child
• Child, Preschool
• Female
• Genotype
• Humans
• Infant
• Leukemia, B-Cell (diagnosis, drug therapy, genetics)
• Male
• Methotrexate (adverse effects)
• Peptide Synthases (genetics)
• Polymorphism, Genetic
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (genetics)
• Prognosis